Dr Reddy’s expands pact with Gilead for investigational HIV prevention drug

The use of twice-yearly lenacapavir for HIV prevention is also approved by the USFDA and the European Medicines Agency; the WHO also recommends twice-yearly lenacapavir in its guidelines for HIV prevention